Cutaneous Lymphoid Hyperplasia Treated with Rituximab: Report of 4 Patients

Document Type : Case Report

Authors

1 Resident, Skin Diseases and Leishmaniasis Research Center AND Department of Dermatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Professor, Skin Diseases and Leishmaniasis Research Center AND Department of Dermatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 General Practitioner, Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran AND Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Cutaneous benign lymphoid hyperplasia (CLH) is a B-cell pseudolymphoma of unknown origin and the most involving site is the face.Case Report: This report presents 4 CLH patients treated with rituximab.Conclusion: Rituximab may be useful for resistant or relapsing forms of CLH who failed other forms of therapy.

Keywords

References

  1. Anandasabapathy N, Pulitzer M, Epstein W, Rosenman K, Latkowski JA. Pseudolymphoma evolving into diffuse large B-cell lymphoma. Dermatol Online J 2008; 14(5): 22.
  2. Benchikhi H, Bodemer C, Fraitag S, Wechsler J, Delfau-Larue MH, Gounod N, et al. Treatment of cutaneous lymphoid hyperplasia with thalidomide: report of two cases. J Am Acad Dermatol 1999; 40(6 Pt 1): 1005-7.
  3. Dadban A, Truchetet F. Cutaneous lymphoid hyperplasia on a preexistent melanocytic nevus. Dermatology 2008; 217(3): 199-200.
  4. Gilliam AC, Wood GS. Cutaneous lymphoid hyperplasias. Semin Cutan Med Surg 2000; 19(2): 133-41.
  5. Good LM, Miller MD, High WA. Intralesional agents in the management of cutaneous malignancy: a review. J Am Acad Dermatol 2011; 64(2): 413-22.
  6. Guis S, Schiano de Colella JM, Bonnet N, Andrac-Meyer L, Balandraud N, Mattei JP, et al. Cutaneous pseudolymphoma associated with a TNF-alpha inhibitor treatment: etanercept. Eur J Dermatol 2008; 18(4): 474-6.
  7. Khan AQ, Tolat T, Patil A. Cutaneous lymphoid hyperplasia presenting as bilateral post-auricular swellings: a case report. International Journal of Science and Research 2015; 4(2): 2366-8.
  8. Lackey JN, Xia Y, Cho S, Sperling LC. Cutaneous lymphoid hyperplasia: a case report and brief review of the literature. Cutis 2007; 79(6): 445-8.
  9. Luger T, Paul C. Potential new indications of topical calcineurin inhibitors. Dermatology 2007; 215(Suppl 1): 45-54.
  10. Martin SJ, Duvic M. Treatment of cutaneous lymphoid hyperplasia with the monoclonal anti-CD20 antibody rituximab. Clin Lymphoma Myeloma Leuk 2011; 11(3): 286-8.
  11. Paul T, Radny P, Krober SM, Paul A, Blaheta HJ, Garbe C. Intralesional rituximab for cutaneous B-cell lymphoma. Br J Dermatol 2001; 144(6): 1239-43.
  12. Taylor RB, Fortney JA, Pollack RB, Metcalf JS, Jenrette JM. Radiation therapy for B-cell cutaneous lymphoid hyperplasia. Jpn J Radiol 2010; 28(5): 385-7.
  13. Tomar S, Stoll HL, Grassi MA, Cheney R. Treatment of cutaneous pseudolymphoma with interferon alfa-2b. J Am Acad Dermatol 2009; 60(1): 172-4.
  14. Valencak J, Weihsengruber F, Rappersberger K, Trautinger F, Chott A, treubel B, et al. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients. Ann Oncol 2009; 20(2): 326-30.
  15. Witzig TE, Inwards DJ, Habermann TM, Dogan A, Kurtin PJ, Gross JB, et al. Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab. Mayo Clin Proc 2007; 82(6): 692-9.
Journal of Isfahan Medical School
Volume 34, Issue 371 - Serial Number 371
January and February 2016
Pages 114-119

Files

History

  • Receive Date: 21 November 2015
  • Revise Date: 06 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics